Home LiteratureArticle Details
PMID: 4038058 Published · ppublish English Journal Article

Late relapse from cutaneous stage I malignant melanoma.

Archives of surgery (Chicago, Ill. : 1960) ·Vol. 120 ·No. 10 ·1985-10-00 ·Pages 1155-9

Shaw HM, Beattie CW, McCarthy WH, Milton GW

Abstract

In 1,283 patients with cutaneous stage I malignant melanoma who had ten or more years of follow-up, the incidence of late recurrence (first evidence of metastases occurring ten or more years after melanoma diagnosis) was 2.7%. None of the factors of prognostic importance (anatomic site, tumor thickness, ulcerative state of primary lesion, or initial surgical treatment) proved useful in predicting those patients with late recurrence. There was no sex or age difference in either incidence of late recurrence or prognosis subsequent to recurrence. Prognosis subsequent to late recurrence depended on the site of the recurrence. Survival after distant metastases became evident was extremely short. However, in the majority (53%) of patients, late recurrence was local and survival subsequent to treatment of these metastases was often protracted, emphasizing the importance of long-term follow-up in all patients with cutaneous melanoma.

MeSH Terms
Adult Female Humans Male Melanoma/pathology Neoplasm Metastasis Neoplasm Recurrence, Local/mortality,pathology Neoplasm Staging Prognosis Skin Neoplasms/pathology Time Factors
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Shaw H M
Beattie C W
McCarthy W H
Milton G W
Article Info
Journal
Archives of surgery (Chicago, Ill. : 1960)
Abbr.
Arch Surg
ISSN
0004-0010
Published
1985-10-00
Pages
1155-9
Language
English
Region
United States
NLM ID
9716528
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com